Rubicon Research (NSE:RUBICON) Notes Receivable: ₹0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:RUBICON Rubicon Research Ltd NSE:RUBICON
18 GF Score
Price ₹1,439.60
! 3 Warning Signs
View Full Analysis

What is Rubicon Research Notes Receivable?

Rubicon Research NSE:RUBICON +1.45% 18 Notes Receivable is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:RUBICON with a GF Score™ of 18/100. The stock has 3 warning signs investors should review.

Rubicon Research's Notes Receivable for the quarter that ended in Mar. 2026 was ₹0 Mil.

Rubicon Research Notes Receivable Related Terms

Rubicon Research Notes Receivable Historical Data

* Premium members only.

The historical data trend for Rubicon Research's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rubicon Research Notes Receivable Chart

Rubicon Research Annual Data
Trend Mar23 Mar24 Mar25 Mar26
Notes Receivable
0.00 0.00 0.00 0.00

Rubicon Research Quarterly Data
Mar23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
NSE:RUBICON
18GF Score
Rubicon Research Ltd NSE:RUBICON
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rubicon Research Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of ₹0 Mil mean?
Rubicon Research (NSE:RUBICON) has a Notes Receivable of ₹0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Rubicon Research and its competitors.
Is Rubicon Research's Notes Receivable too high?
Rubicon Research's current Notes Receivable is ₹0 Mil. Overall, Rubicon Research has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Rubicon Research's Notes Receivable compare to LLY and JNJ?
Rubicon Research's Notes Receivable of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Rubicon Research and its competitors. Rubicon Research's current Notes Receivable is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rubicon Research stock overvalued right now?
Rubicon Research (NSE:RUBICON) has a current Notes Receivable of ₹0 Mil. The current Notes Receivable is ₹0 Mil. Rubicon Research's overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Rubicon Research (NSE:RUBICON), the current Notes Receivable is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rubicon Research Business Description

Other Exchanges 544578:India
Address Road No. 33, MedOne House, B-75, Wagle Estate, Thane West, Thane, MH, IND, 400 604
Rubicon Research Ltd is a pharmaceutical formulations company specializing in developing, manufacturing, and marketing branded specialty and generic prescription products. Starting as a provider of contract formulation development services, the company expanded to operate an oral solids manufacturing facility in India, offering contract development and manufacturing services for regulated markets. The company's diverse product portfolio covers multiple therapeutic areas, including analgesics and pain management, CVS, CNS, hypokalemia, skeletal muscle relaxants, NRT, gastrointestinal, metabolic, and immunosuppressants. The company operates in India, the USA, and other markets, with the majority of its revenue coming from the USA.
18GF Score

Get the complete analysis for NSE:RUBICON

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,439.60
Price